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Background: Genital warts caused by human papillomavirus (HPV) infection are the most common sexually
transmitted disease leading to anogential lesions. Although the laser therapy has been shown to be effective in a
number of conditions, the use of laser diode vaporization in urological applications and the understanding on its
effectiveness as a treatment for various urological conditions is limited. Therefore, the aim of this study was to
evaluate the efficacy of diode laser vaporization as a treatment for genital lesions.
Methods: Patients presenting with genital lesions at the urology outpatient clinic at Coronel Mota Hospital, between
March 2008 and October 2014, were enrolled into the study. Data collected included age, gender, duration of the
lesion, site of the lesion and numbers of the lesions, length of follow-up, recurrence of lesions after treatment and
whether there were any complications.
Results: A total of 92 patients were enrolled in the study; 92.4% (n = 85) male; mean age (± SD) 27.92 ± 8.272 years.
The patients presented with a total of 296 lesions, with a median of 3 lesions each, including penis (n = 78), urethra
(n = 4) lesions, and scrotum (n = 2) lesions. Lesions ranged in size from 0.1 to 0.5 cm2, most commonly 0.3 cm2 (n = 38;
41.3%), 0.4 cm2 (n = 21; 22.8%) or 0.5 cm2 (n = 20; 21.7%). Patients most commonly reported that they had their lesions
for a duration of 12 (n = 29; 31.5%) or 6 months (n = 23; 25.0%). Eighteen patients (19.6%) had a recurrence after their
1st/conventional treatment. There were no incidences of post–operative infection or complications from the laser diode
vaporization.
Conclusions: Laser diode vaporization can be considered as an alternative method for treating genital lesions in
urology, with satisfactory results in terms of pain, aesthetic and minimal recurrence.
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Genital lesions are a relatively common condition which
may be caused either by sexually transmitted human
papillomavirus (HPV) infection, as a result of non–infec-
tious inflammatory diseases such as psoriasis and lichen
planus, by a drug reaction and also as premalignant le-
sions that can progress to carcinoma. Regardless of ori-
gin, genital lesions are both a source of considerable
discomfort and a cause of embarrassment and psycho-
logical repercussions. Genital lesions can often persist
for prolonged periods, frequently a number of years and
can re–occur after treatment.* Correspondence: mmljr@uol.com.br
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unless otherwise stated.Genital warts caused by HPV are the most common
sexually transmitted disease and a major cause of ano-
gential lesions. In addition to physical and psychological
implications of HPV warts, there is also a substantial
economic cost, estimated at $6 billion annually in the
United States [1]. No specific antiviral therapies are
available to cure HPV anogenital warts; treatment there-
fore relies on removal of warts or limiting spread
through anti-proliferative or immunomodulation therapy
[2]. However recurrence rates can be high due to the
widespread infection or subclinical lesions that are not
identified at the time of treatment. The variety of differ-
ent treatment options for genital warts can be loosely
grouped into three categories: topical agents, systemic
agents, and surgical therapies [2].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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across dermatological conditions is diode laser therapy.
Diode lasers are semiconductors that change electrical
energy into light energy through the use of solid‑state el-
ements, such as aluminum and gallium. The light beam
which is released by the diode laser falls within the vis-
ible and invisible range of near infrared waves (with
wavelengths varying between 800 and 980 nm) and is
able to vaporize soft tissue due to its high water content.
These light beams are poorly absorbed by the hard tissue
and therefore do not damage nearby hard tissue. By fo-
cussing the beam on the desired area for incision, a
highly precise focal spot can be created. By adjusting the
focus of the beam, the intensity of the laser light can be
varied, which allows cauterization of small blood vessels
and lymphatics to decrease post–operative swellings and
sealing of nerve endings to reduce post-operative pain
[3-5]. Studies suggest that side effects of diode laser
therapy are generally mild [6-9]. However laser therapy
can be expensive and is not widely available. Research to
determine the efficacy of laser therapy for the treatment
of different conditions is therefore important in order to
justify investment in laser equipment and training in the
use of laser therapy.
Laser therapy has been shown to be effective in a
number of conditions, with probably the largest body of
work conducted to examine the efficacy of laser surgery
for the removal of different oral lesions such as simple
soft tissue surgery (e.g. frenectomy, gingival contouring
plasty) [3,10-12], vascular lesions (e.g. hemangiomas,
telangiectasias) [4,5] and pigmented lesions [3]. Other
areas where lasers have become a key option for treat-
ment include cosmetic applications such as laser hair
removal and laser tattoo removal, and various dermato-
logical applications, including conditions such as syrin-
goma, xanthelasma palpebrarum, recalcitrant warts,
rhinophyma, epidermal nevi, condyloma and intrae-
pithelial neoplasia and milia [13-19]. These studies have
suggested a number of advantages of laser surgery over
traditional scalpel surgical procedures, such as greater
precision, a relatively bloodless surgical and postsurgi-
cal course, sterilization of the surgical area, minimal
swelling and scarring, coagulation, vaporization, cut-
ting, minimal or no suturing, and less or no postsurgi-
cal pain [12].
There have been few studies to date that have exam-
ined the efficacy of laser therapy as a destructive therapy
for genital warts [20-23]. Because warts are vascular,
laser therapy should result in instant coagulation and
therefore provide bloodless removal of the lesion. The
few studies of genital lesions conducted to date suggest
clearance rates ranging between 23% and 52% for carbon
dioxide and pulse dye laser therapy; however recurrence
rates as high as 77% have also been reported [19,20,22].However, the description of the use of laser diode
vaporization in urological applications is still limited,
and further work is required to fully understand the
effectiveness of laser diode vaporization as a treatment
for various urological conditions. The aim of this study
was therefore to evaluate the efficacy of diode laser
vaporization treatment in genital lesions.
Methods
Study population
This was a prospective study of patients presenting with
genital lesions between March 2008 and October 2014.
The study was conducted in the urology department
outpatient clinic at Coronel Mota Hospital. Patients
were eligible to be enrolled in the study if they presented
with a genital lesion and were willing to provide in-
formed written consent to the study. No other eligibility
criteria were applied. The study was conducted under
the ethical approval provided by ethical review board of
Coronel Mota Hospital.
Data collection
Following consent, a full demographic and medical his-
tory was taken for each participant. Data collected in-
cluded age, gender, duration of the lesion, site of the
lesion and number of the lesions, length of follow-up,
recurrence of lesions after treatment and whether there
were any complications.
Diagnosis and treatment protocol
Upon presentation and written consent to participate in
the study, patients underwent a physical examination to
diagnose the lesion/s. No additional endoscopy was used
at for diagnosis. Each patient then underwent laser diode
vaporization of their lesion/s according to a standardized
protocol. Firstly the warts lesion was prepared by steril-
izing the area with povidone-iodine solution (10%) and
infiltrating locally with 2% xylocaine hydrochloride with-
out adrenalin. The laser light was then applied using ei-
ther a circular or radial contact method. In all cases a
Zap Laser, LLC® model Z2006AP was used, with a power
density of 1.2 W/cm2 CW (continue wave). Laser treat-
ment was generally applied for 5–15 seconds for each le-
sion. For patients with a larger number of lesions, multiple
treatment sessions were used. For example, for a patient
with 10 lesions, a total of 4 treatment sessions were used.
Patient follow-up
After treatment, patients were seen at 7 days in order to
check for early post-operative complications. They were
then followed up at approximately 4 weeks intervals for
12 weeks. Any associated complications that occurred
during this time, such as infection, scarring, hyperpigmen-
tation, hypo- pigmentation or any other sequelae, were
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patients continued at the end of the 12 weeks in order to
collect data on potential longer term complications.
Results
Patient characteristics
A total of 92 patients were enrolled in the study, of which
7 (7.6%) were female and 85 (92.4%) were men (Table 1).
All patients were treated with diode laser due to verrucoid
lesions (<0.5 cm2) in genital and skin. The mean age of the
study cohort was 27.92 ± 8.272, ranging from 15 to 53 years.
Together, the participants had a total of 296 lesions; this in-
cluded one patient who had more than 10 lesions. Most
commonly patients had three (n = 28; 30.4%), two (n = 18;
19.6%), four (n = 14; 15.2%), or five 5 (n = 15; 16.3%) le-
sions, with the median number of lesions being three. The
lesions ranged in size from 0.1 to 0.5 cm2, most commonly
0.3 cm2 (n = 38; 41.3%), 0.4 cm2 (n = 21; 22.8%) or 0.5 cm2
(n = 20; 21.7%). A total of 78 patients had penis lesions,
whilst four had external urethral meatus lesions, two had
scrotum lesions, one had an anal mucosa lesion, and there
were seven participants who had lesions on their face or
neck (four with lesions on the neck, two with oral lesions
and one with lesions on their face). A further four patients
had a frenulectomy and therefore no lesions were reported
for these patients.
Patients most commonly reported that they had had
their lesions for a duration of 12 (n = 29; 31.5%) or
6 months (n = 23; 25.0%), with reported durations ranging
from 1 to 36 months. A total of 18 patients (19.6%) had
had a recurrence after their 1st/conventional treatment.
Treatment outcomes
Figure 1 shows examples from three cases of genital le-
sions before treatment, immediately post laser treatment
and 15 days post laser treatment. Post-operative infection
was not observed in any of the patients. Mild pain, oozing,
oedema, and scales were observed during the first seven
days after laser irradiation. Depending on the size of the le-
sions the healing process, which usually occurs by granula-
tion tissue formation, took between 2–3 weeks. Patient
follow up continued for between 2 months and 6 years
(mean 33.90 ± 25.68 months) after the intensive follow-up
period. No complications from the laser diode vaporization
were observed, including no reported problems with urin-
ation or ejaculation and no strictures or scars.
Discussion
In our study we have evaluated the effect of diode laser
vaporization for the treatment of genital warts. The
treatment protocol used in our study is comparable to
that used in the previous small studies examining pulsed
dye laser therapy for the treatment of genital warts [22].
We found only a small incidence of recurrence after
Figure 1 Representative images from the three genital lesion cases taken before the treatment, immediately after laser treatment and 15 days
post-treatment.
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ies have varied largely, with one study reporting a recur-
rence rate of 12.6% at one month post-laser therapy,
whilst others have reported recurrence rates as high as
77% using carbon dioxide laser and pulsed dye laser
[19,20,22]. Variation in reported recurrence rates may
partially reflect the varying follow-up times within the in-
dividual studies. Some minimal discomfort and oedema
was observed during the immediate period post–laser
treatment, as expected and in line with findings in previ-
ous studies [24]. Notably, we also observed no long-term
complications in any of the patients enrolled in the study,
which is in line with previous reports of the excellent
safety profile of laser therapy as a treatment for genital
warts [9,19,22]. Importantly our study supports reports in
the literature that laser treatment decreases post-operative
pain by sealing nerve endings and reduces blood loss by
cauterizing blood vessels [12].
We found no evidence of infection in any of the pa-
tients within our study. This may be expected since laser
beams have a natural sterilization effect, causing the
evaporation of bacteria, viruses and fungi within the im-
mediate vicinity of the beam and therefore decreasing
the possibility of local infection.
Conclusion
Our study suggests that laser diode vaporization pro-
vides a good option for the treatment of genital lesions.Laser diode vaporization appears to provide a good
clearance rate for the elimination of the verrucae,
whilst at the same time having a low complication and
side–effect profile, in terms of scarring and post-
operative pain, and a low incidence of recurrence.
Therefore laser diode vaporization can be considered
as an alternative method for treating genital lesions in
urology, with satisfactory results in terms of pain, aes-
thetic and minimal recurrence.Consent
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the publication of this report and any accompanying images.
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